Professor Sir Richard Peto
Emeritus Professor of Medical Statistics and Epidemiology
Sir Richard Peto, FRS, is Emeritus Professor of Medical Statistics and Epidemiology at the University of Oxford. He was made a Fellow of the Royal Society of London in 1989 for introducing meta-analyses of randomised trials, was knighted by Queen Elizabeth in 1999 for services to epidemiology, and received in 2010 and 2011 the Cancer Research UK and the BMJ Lifetime Achievement Award.
Richard Peto, Rory Collins and others in the Oxford CTSU have, by their large randomised trials, large prospective studies and worldwide meta-analyses, increased substantially the estimated importance of blood lipids, blood pressure and smoking as causes of premature death. Peto has recently collaborated in major studies of alcohol in Russia and of malaria in Africa and India. His investigations into the worldwide health effects of smoking and benefits of stopping at particular ages have helped to communicate effectively the vast and growing burden of disease from tobacco use, have helped change national and international attitudes about smoking and public health, and have helped many smokers to stop. He was the first to describe clearly the future worldwide health effects of current smoking patterns, predicting one billion deaths from tobacco in the present century if current smoking patterns persist, as against 'only' 100 million in the 20th century.
Cognitive and social activities and long-term dementia risk: the prospective UK Million Women Study.
Floud S. et al, (2021), Lancet Public Health, 6, e116 - e123
Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults
LACEY BEN. et al, (2021), International Journal of Epidemiology
Changes in the diagnosis and management of diabetes in Mexico City between 1998-2004 and 2015-19
Aguilar-Ramirez D. et al, (2021), Diabetes Care
Alcohol consumption and cause-specific mortality in Cuba: prospective study of 120 623 adults
Rojas NA. et al, (2020), EClinicalMedicine
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
PAN H. and Peto R., (2020), MedRxiv